Combination of Umbralisib, Ublituximab, and Bendamustine is Safe and Highly Active in Patients with Advanced DLBCL and Follicular Lymphoma

Drug Category: Array
Conference Category: Array
Lead Author: Lunning M, et al.
Published Date: 03/12/2018
Download Link: /wp-content/uploads/2019/03/ASH-2018-U2-Benda-Lunning-Final.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top